CellCentric’s magic trio

Why Morningside is backing CellCentric’s single-asset strategy

Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes the undisclosed venture round will be enough to get

Read the full 445 word article

User Sign In